Sterility Concerns Cause Recall
Wells Pharmacy Network is voluntarily recalling all of its products due to sterility concerns.
On Sept. 20, 2016, Wells Pharmacy Network announced it was voluntarily recalling all of its sterile human and veterinary products prepared between Feb. 22, 2016 and Sept. 14, 2016 because of FDA concerns regarding a lack of sterility assurance. The company states that no adverse events have been reported as of Sept. 20, 2016.
The company is advising patients and providers to discontinue use of the recalled products and contact the company regarding the return of unused products. Adverse events in humans can be reported through FDA’s MedWatch webpage. Animal adverse events can be reported to FDA on their veterinary safety report page. The company’s press release includes a list of all recalled products.
Source: FDA
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
